To examine treatment patterns following basal insulin (BI) introduction in type 2 diabetes mellitus (T2DM) patients under real-world conditions across China.
| INTRODUCTION

Type 2 diabetes mellitus (T2DM) is a major public health challenge in
China. According to a recent study, the estimated prevalence of diabetes among a representative sample of Chinese adults was 11.6%. 1 Despite this high prevalence, awareness of diabetes among those affected has not increased, 2 and only approximately 40% of those treated have adequate glycaemic control. 1, 3 Because of the progressive nature of T2DM, insulin therapy is eventually indicated for many patients who fail treatment with oral hypoglycaemic agents. Diabetes guidelines in general recommend adding basal insulin (BI) or pre-mixed insulin to existing oral agents as the initial insulin regimen, [4] [5] [6] [7] [8] and sometimes bolus insulin combined with BI or pre-mixed insulin is preferable for managing patients with more severe postprandial hyperglycaemia which is more common in Asian subjects. 9, 10 In clinical practice, the most commonly used BIs are intermediate-acting neutral protamine Hagedorn (NPH) insulin and long-acting insulin analogues glargine and detemir. Numerous randomized controlled trials (RCTs) have demonstrated the efficacy of these agents in glycaemic control. 11 Many RCTs have established the importance of active titration of basal, pre-mixed or prandial insulin in achieving and maintaining glycaemic control. [12] [13] [14] [15] Despite the merits of RCTs in determining the efficacy of interventions, the overall effectiveness of interventions depends on use under pragmatic or real-life conditions. 16 Previous real world, observational studies have shown delayed intensification of the insulin regimen, 17 insufficient blood glucose monitoring and, hence, limited insulin dose titration, which were identified as barriers to achieving better glycaemic control with insulin. 18 Several observational studies have prospectively examined the real-life initiation of BI in patients uncontrolled by oral antihyperglycaemic drugs (OADs) in China; however, these studies included only limited numbers of patients, clinical settings or types of BI. 19, 20 In order to obtain a more comprehensive picture of real-life BI treatment, we performed a large-scale, prospective, observational study of BI use to investigate patterns of BI initiation, evolution of treatment regimens, glycaemic outcomes and safety. We believe that findings from this study will be valuable in optimizing the use of BI in China and even globally.
| MATERIALS AND METHODS
| Study design
ORBIT was a multicentre, observational, 6-month prospective registry study in China. 
| Statistical methods
A basic analysis set comprising 16 341 patients with either HbA1c or weight measurements at 6 months was used to describe the initial regimens and the evolution of treatment regimens as well as glycaemic outcomes and SAEs at each visit. The dose and titration of insulin as well as hypoglycaemia and weight gain during follow-up were analysed based on 11 417 participants who continued using BI at visits 2 and 3, while the counterparts for all available participants at each visit were also analysed and are presented in Tables S1 to S6 . 
| RESULTS
| Participant characteristics
During a recruitment period of 1.5 years, 18 995 patients from 209 hospitals (105 secondary and 104 tertiary) qualified for recruitment at visit 1. Detailed baseline characteristics at visit 1 were described in a different publication. 21 Of the 18 995 participants recruited at baseline, 16 341 completed the 6-month follow-up and data from these patients were used for analysis in the study ( Figure 1 Participants without a successful clinical visit within a 1-month follow-up window at visits 2 or 3 were defined as lost to follow-up.
At the end of study, 2654 patients were lost to follow-up. No clinically significant difference in baseline characteristics was found between patients who completed follow-up and those who did not (Table S1 ). switched to pre-mixed insulin and 22.1% (644) discontinued. total insulin are also displayed in different subgroups in Table 2 . Similar results can be found online in Table S2 in which all available participants at each visit, including those who continued and discontinued insulin treatment, were analysed. A similar trend of insulin dose titration is shown in Tables S3 and S4 in which basal and total insulin dose titration is described per baseline HbA1c range, respectively.
| Proportion of OAD types before and after adding BI
| Initial regimens and adherence to BI treatment
| Initial dose and subsequent dose titration of insulin
Changes in BI dose were minimal during follow-up (Table 2) .
Among participants who continued using insulin until visit 2 or visit 
| Glycaemic outcomes
| Safety and body weight changes
Mean body weight at visits 1 and 3 was similar (Table 3) . Table 3 shows the frequency of hypoglycaemia (severe and minor) and body weight in different subgroups at visits 1 and 3. (Tables S5   and S6 ).
During the 6-month study period, a total of 539 (3.3%) participants experienced at least 1 SAE (with a total of 582 SAEs); among these, 93.0% resulted in hospitalization. A total of 24 SAEs were 1 Only participants included at both baseline and month 6 were used.
2 Pre-mixed insulin with or without OADs.
reported to be related to antidiabetic treatment, 13 being related to OADs and 11 being related to insulin (9 resulted in hospitalization, 1 lengthened the term of hospitalization and 1 had another impact). 1 Minor hypoglycaemia was documented in the past month.
| DISCUSSION
2 Severe hypoglycaemia was documented in the past 3 months.
SOLVE study (10 AE 7 years), the average duration of known diabetes was significantly shorter in the ORBIT study (6.4 AE 5.3 years). This was explained mainly by the fact that more participants undergoing OAD monotherapy were recruited into the ORBIT study (46.0%) than were recruited into the SOLVE (29.9%) study and the FINE (19.2%) study. At 6 months, the HbA1c and FPG levels were substantially lower than those at baseline. This was similar to the change described in the observational A1chieve study, 25 which found a mean change in from baseline to 2 to 6 months after treatment. 26 The HbA1c control rate in our study was 40.8%, which was higher than that in the Asian population in the FINE study (33.7%); however, patients in that study had a longer mean duration of diabetes (9.3 years) compared with the present study (6.4 years). 1 Based on participants who continued using basal insulin during follow-up.
2 Documented as the number of episodes during the past 1 month for severe hypoglycaemia or during the past 3 months for minor hypoglycaemia at each visit and converted to the number of episodes/100 patient-years.
RCTs indicate that addition of BI to the treatment regimen for 34 it is understandable that the higher reduction in HbA1c can be attributed to the higher baseline HbA1c in our study. It has also been well documented that higher baseline HbA1c
is associated with a lower proportion of patients reaching target
HbA1c levels during follow-up. 35, 36 Therefore, the percentage of patients achieving the HbA1c target should also be considered when assessing the efficacy of insulin therapies.
Another possible reason for higher reduction of HbA1c in our study might be the relative positive use of premixed insulin or prandial insulin in Asians, where postprandial hyperglycaemia occurs more often than in other regions 10 and pre-mixed insulin has been reported as an effective therapeutic option for patients with suboptimal glucose control. 37 However, despite the significant reduction of HbA1c in the real-world ORBIT study, the majority of participants still did not achieve the target HbA1c level at the end of follow-up, emphasizing the probable inadequate dose titration.
Weight gain during follow-up was minimal, although the study design precludes attribution of such changes to BI initiation. For participants receiving BI, minor hypoglycaemia frequency did increase. This was mainly seen in participants using NPH insulin and insulin detemir; however, because of the nature of the study design, direct comparisons cannot be drawn. A year-long, randomized, non-inferiority study in 582 insulin-naïve T2DM patients compared clinical outcomes following addition of insulin glargine or insulin detemir to OADs and found effective glycaemic control and a low rate of hypoglycaemia with both BIs; however, insulin detemir was associated with more injection-site reactions and less weight gain compared with insulin glargine. 38 The initial dose of BI in the ORBIT study was 0.18 AE 0.07 IU/ kg/d, which is consistent with the dose recommended by several guidelines. 5, 6, 8 In addition, these guidelines also recommend that BI alone is the most convenient initial insulin regimen, beginning at 10 IU or 0.1 to 0.2 IU/kg, depending on the degree of hyperglycaemia. At 6-month follow-up, the mean daily dose of BI and total insulin increased by only 0.03 and 0.02 IU/kg (P < .001), respectively. Considering that nearly 60% of patients did not achieve the target of there is a severe shortage of personnel for teaching patients the selfmanagement skills for insulin injection and titration, which results in poor or no self-titration of insulin. 39 Accordingly, efforts to improve these issues are urgently needed to achieve timely insulin initiation and adherence, as well as appropriate dose titration in Chinese T2DM patients.
Strengths of this study are those inherent in its observational design, reflecting the actual use of therapies, 40 including the large sample size (almost 20 000 participants) drawn from all major regions in China among a clinically relevant heterogeneous population. This enables ecologically valid assessment of the effects of introduction of BI regimens, switches in regimens and diversity at the regional and hospital levels during real-life clinical practice. However, studies have suggested that Asians make a higher contribution to postprandial hyperglycaemia, with better response to premixes, and they require more mealtime insulin coverage, in contrast to non-Asians. 10 This introduces a limitation to generalization of Chinese data to other ethnicities.
In conclusion, in real-world clinical settings in China, this observational study has found that initiation of BI treatment is associated with significant improvement in glycaemic control without overtly compromising safety related to hypoglycaemia and weight gain. However, patients with T2DM tend to have very poor blood glucose control and a high prevalence of diabetic complications before initiating insulin treatment, and the insulin dose titration is quite inadequate after initiation. More quality improvement work is needed to improve regular glucose monitoring and adequate adjustment of medication, including timely initiation of insulin and more active insulin dose titration.
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